Vaidika Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 21-12-2024
- Paid Up Capital ₹ 0.10 M
as on 21-12-2024
- Company Age 7 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2022)
- Profit 9.14%
(FY 2022)
- Ebitda 22.70%
(FY 2022)
- Net Worth -21.14%
(FY 2022)
- Total Assets -7.37%
(FY 2022)
About Vaidika Pharma
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Ketaki Mane, Amit Thakral, and Abhijit Waghmare serve as directors at the Company.
- CIN/LLPIN
U74999PN2017PTC173099
- Company No.
173099
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Oct 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Vaidika Pharma Private Limited offer?
Vaidika Pharma Private Limited offers a wide range of products and services, including Turnkey Consultants & Solutions, Project Consultants, Cereals & Food Grains, Basmati Rice, Fresh, Dried & Preserved Fruits, Frozen Fruits, Bird Food, Poultry & Animal Food, Fish Foods, Landscape Structure and Designing, Gardening Service.
Who are the key members and board of directors at Vaidika Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ketaki Mane  | Director | 23-Oct-2017 | Current |
| Amit Thakral | Additional Director | 13-Oct-2022 | Current |
| Abhijit Waghmare | Director | 23-Oct-2017 | Current |
Financial Performance of Vaidika Pharma.
Vaidika Pharma Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a slight improvement in profitability, with a 9.14% increase in profit. The company's net worth observed a substantial decline by a decrease of 21.14%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vaidika Pharma?
In 2020, Vaidika Pharma had a promoter holding of 100.00%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Vaidika Pharma?
Unlock and access historical data on people associated with Vaidika Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vaidika Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vaidika Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
